Literature DB >> 3390392

A simple method for culturing myeloma cells from human bone marrow aspirates and peripheral blood in vitro.

B C Millar1, J B Bell, A Lakhani, M J Ayliffe, P J Selby, T J McElwain.   

Abstract

A double layer agar technique has been developed to grow myeloma colonies (MY-CFUc) from human bone marrow aspirates and peripheral blood. Heavily irradiated HL60 cells (5 x 10(5)/plate) are added to an agar underlay in growth medium containing 0.5% agar. Mononuclear cells from the test bone marrow or blood are overlayered in either 0.2 ml HL60-conditioned medium (HL60-CM) or in 0.5 ml growth medium containing 0.23% agar, and the cultures are incubated at 37 degrees C in an atmosphere of 5% CO2, 10% O2 and 85% N2. Colonies (greater than 50 cells) form between 2 and 3 weeks. Using this method 60/68 samples of bone marrow and 7/12 samples of blood from 54 patients have produced colonies in soft agar and in liquid on an agar underlay. The cells which form these colonies are of two distinct sizes, the larger cells being plasmacytoid and the smaller lymphoid. The two cell types are usually, but not always, present in separate colonies. Both plasmacytoid and lymphoid cells carry the isotype of the respective patient's myeloma protein and the plasma cell marker (HAN PC1). This technique has enabled us to culture myeloma cells from patients with as few as 2% plasma cells in the bone marrow but it does not permit the growth of normal B, T or granulocyte-macrophage colonies (GM-CFUc). The drug sensitivity of myeloma cells (MY-CFUc) compared with normal haemopoietic cells (GM-CFUc) can be measured using dose-response curves in individual patients. Furthermore, this method can detect resistant subpopulations within a given myeloma sample.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3390392     DOI: 10.1111/j.1365-2141.1988.tb07622.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  8 in total

Review 1.  Oncology.

Authors:  J S Malpas
Journal:  Postgrad Med J       Date:  1990-02       Impact factor: 2.401

2.  Characterization of clonogenic multiple myeloma cells.

Authors:  William Matsui; Carol Ann Huff; Qiuju Wang; Matthew T Malehorn; James Barber; Yvette Tanhehco; B Douglas Smith; Curt I Civin; Richard J Jones
Journal:  Blood       Date:  2003-11-20       Impact factor: 22.113

3.  Melphalan transport into human malignant lymphoid cells differs from the murine equivalent in vitro.

Authors:  B C Millar; J A Maitland; J L Millar; J B Bell
Journal:  Br J Cancer       Date:  1989-05       Impact factor: 7.640

4.  Atiprimod blocks STAT3 phosphorylation and induces apoptosis in multiple myeloma cells.

Authors:  M Amit-Vazina; S Shishodia; D Harris; Q Van; M Wang; D Weber; R Alexanian; M Talpaz; B B Aggarwal; Z Estrov
Journal:  Br J Cancer       Date:  2005-07-11       Impact factor: 7.640

5.  CRISPR/Cas9 mediated knock-out of VPREB1 gene induces a cytotoxic effect in myeloma cells.

Authors:  Mai Khaled; Amr S Moustafa; Nashwa El-Khazragy; Maha Imam Ahmed; Marwa Ali Abd Elkhalek; Eman M El Salahy
Journal:  PLoS One       Date:  2021-01-08       Impact factor: 3.240

6.  Neutralising antibodies in patients with multiple myeloma receiving maintenance therapy with interferon alpha 2b.

Authors:  J B Bell; R Barfoot; T Iveson; R L Powles; B C Millar
Journal:  Br J Cancer       Date:  1994-10       Impact factor: 7.640

7.  Evidence that multiple myeloma may be regulated by homeostatic control mechanisms: correlation of changes in the number of clonogenic myeloma cells in vitro with clinical response.

Authors:  J A Maitland; B C Millar; J B Bell; A Montes; J Treleaven; M E Gore; T J McElwain
Journal:  Br J Cancer       Date:  1990-03       Impact factor: 7.640

8.  The proliferation of multiple myeloma colonies (MY-CFUc) in vitro is independent of prognosis and is not associated with mutated N- or K-ras alleles in human bone marrow aspirates.

Authors:  B C Millar; J B Bell; R Barfoot; M Everard
Journal:  Br J Cancer       Date:  1995-02       Impact factor: 7.640

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.